Marimastat Dosing for Post-Insult Epileptogenesis Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epileptogenesis, such as marimastat, are limited by severe side effects that prevent long-term use, and there is a need for an effective and safe therapeutic agent to prevent or treat this condition.
Innovation Solution
The use of marimastat, a matrix metalloproteinase inhibitor, to prevent or treat epileptogenesis by inhibiting MMP-9 activity, administered orally or via other routes, with specific dosing regimens to minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If marimastat is used to treat epileptogenesis, then seizure frequency and severity are reduced, but severe side effects occur that prevent long-term use
Solution Approach 1:
The patent applies parameter changes by optimizing the dosing regimen of marimastat - using lower doses (10 mg/kg b.w.) and shorter treatment courses to maintain therapeutic effectiveness while reducing the incidence of severe side effects like arthralgia from 60% to much lower levels
Solution Approach 2:
The patent implements periodic action through short courses of marimastat treatment rather than continuous long-term administration. This approach allows the drug to be effective in preventing epileptogenesis while minimizing cumulative side effects, with treatment interrupted between courses
2Reliability
If higher doses of marimastat are administered, then therapeutic effectiveness increases, but incidence of severe arthralgia increases to 60%
Solution Approach 1:
The patent resolves this contradiction by changing the dosage parameter to 10 mg/kg b.w., which maintains sufficient therapeutic effectiveness for preventing epileptogenesis while reducing the incidence of severe arthralgia from 60% to much lower levels, making long-term treatment feasible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Marimastat effectively inhibits MMP-9-dependent processes in the brain, reducing seizure frequency and severity in animal models of epileptogenesis, demonstrating its potential as a safe and effective treatment.
Implementation Method 1
Marimastat (BB-2516), a compound according to Formula I, is a well-known inhibitor of the enzymes belonging to the family known as matrix metalloproteinases (MMPs)
Implementation Method 2
One of the proteases controlling ECM environment under physiological and pathological conditions is MMP-9 that is a type IV collagenase, with gelatinolytic properties
Data Source
AI summary
The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a pharmaceutically acceptable salt thereof is administered preferably within the first 24 hours after induction of epileptogenesis.